Latest Neotropix Inc. Stories

2009-01-13 06:45:00

Innovative Therapy Ensures Greater Patient Compliance, Improves Quality of Life MOUNTAIN VIEW, Calif., Jan. 13 /PRNewswire/ -- Based on its recent analysis of the biopharmaceuticals market, Frost & Sullivan recognizes Neotropix, Inc. with the 2009 U.S. Frost & Sullivan Award for Product Innovation of the Year. This award acknowledges the company's introduction of the innovative virotherapy NTX-010 (Seneca Valley Virus), an oncolytic picorna virus for treating small cell lung cancer...

2008-10-22 09:00:10

Neotropix(R), Inc., a clinical-stage development company focused on neuroendocrine cancer treatments, announced today exciting data from an extensive pediatric preclinical study performed by the National Cancer Institute (NCI) funded Pediatric Preclinical Testing Program on the use of NTX-010 (Seneca Valley Virus-001), a tumor-selective naturally-occurring oncolytic virus. The results support the initiation of clinical development of Neotropix's lead candidate, NTX-010 for the treatment of...

2008-10-10 11:54:53

Researchers seek to understand, and improve, virus that can infect lung cancer cells The 3-D structure of the virus, known as Seneca Valley Virus-001, reveals that it is unlike any other known member of the Picornaviridae viral family, and confirms its recent designation as a separate genus "Senecavirus." The new study reveals that the virus's outer protein shell looks like a craggy golf ball "” one with uneven divets and raised spikes"”and the RNA strand beneath it is arranged in...

2008-10-08 09:00:12

Neotropix(R), Inc., a clinical-stage development company focused on neuroendocrine cancer treatments, announced today that it has begun enrolling neuroendocrine cancer patients into an expanded clinical trial of its lead candidate, NTX-010 (SVV-001), a tumor-selective naturally-occurring oncolytic virus. Neotropix(R) also announced that it has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) of NTX-010 for the treatment of neuroendocrine tumors. After...

2008-09-23 09:00:15

Neotropix(TM), Inc., a clinical-stage development company focused in neuroendocrine cancer treatments, today announced the appointment of Anthony Williams, M.D., as its Chief Medical Officer (CMO). Dr. Williams has more than 25 years of drug development experience, working for major pharmaceutical and biotechnology companies including GlaxoSmithKline, Merrell Dow and Dyax Corporation. In this new role as CMO, Dr. Williams is the most senior physician of the company with primary...

Word of the Day
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.